This website uses cookies
Read our Privacy policy and Terms of use for more information.
Long Form Content
Jul 7, 2024
•
7 min read
🧬 Winners, Losers, and Upcoming Earnings Calls
Jul 5, 2024
6 min read
Beacon Therapeutics raises $170M Series B, Pentixapharm acquires Glycotope's antibody discovery arm, J&J lands FDA and EMA approval for multi-drug resistant TB therapy, and CureVac sells its Covid-19/flu assets while also laying off 30% of their staff
Jul 3, 2024
9 min read
Eli Lilly lands key Alzheimer's FDA approval, Samsung Biologics scores whopper $1B CDMO contract, Annovis Bio has a great day on positive Ph3 Parkinson's data, and Americans don't know which pharma makes weight-loss drugs
Jul 2, 2024
Eli Lilly makes another radiopharma deal, Samsung's Stelara biosimilar gets FDA approval, Boehringer Ingelheim begins Ph1 for "first-in-class" obesity treatment, Takeda sheds over 200 MA-based staffers, and lone Ph1 ultra-rare disease gene therapy patient makes stellar improvements
Jul 1, 2024
Abbvie, Regeneron, Merck & Co. all land CHMP panel recommendations (while Apellis and PTC both get thumbs down), Lantheus buys radiophama assets, Ensho Therapeutics launches with Eisai assets, and former Cassava Sciences scientific advisor gets indicted
Jun 29, 2024
Jun 28, 2024
Novo Nordisk buys 2seventy bio's hemophilia A asset, worm-derived therapies raise $16M, Abbvie buys Celsius Therapeutics for $250M, Kite Pharma to evaluate Cellares' cell therapy manufacturing platform, and Merck, Daiichi Sankyo's lung cancer mAb hit with FDA CRL
Jun 27, 2024
Novo Nordisk's Wegovy lands China NMPA approval, big DNA edits without CRISPR, Curie.Bio raises $380M VC fund, SK Bioscience buys IDK Biologika controlling stake, and Novo Nordisk's $816M Ph3 oof
Jun 26, 2024
Otsuka and Lundbeck’s PTSD sNDA filing accepted, Exsilio launches with $82M and big name investors, Zealand Pharma ups equity offering to $1B, Eli Lilly & OpenAI sign an antibiotic drug discovery pact, and Abbvie's Parkinson's med gets hit with a CRL
Jun 25, 2024
10 min read
Alnylam’s slam dunk Ph3 heart disease data, Pfizer tapped to supply RSV vaccine to the UK, Novo Nordisk shares detailed hemophilia A Ph3 data, Novo Nordisk earmarks $4.1B for NC manufacturing plant, and Merck KGaA cuts a Ph3 cancer trial short
Jun 24, 2024
8 min read
BMS & Takeda both land colorectal cancer approvals, don't doze on Eli Lilly's sleep apnea data, Tectonic goes IPO via reverse merger, Vertex signs reimbursement deal with NHS, while Ginkgo Bioworks cuts 150+ jobs
Jun 22, 2024
